The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours
Completed
- Conditions
- Major Depressive DisordersSchizophreniaBipolar Disorders
- Registration Number
- NCT01377896
- Lead Sponsor
- AstraZeneca
- Brief Summary
'Real life' retrospective patient cases (10) to provide an objective and robust analytical report of patient management and prescriptions behaviours for Schizophrenia, Bipolar disorders and Major depressive disorders.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 221
Inclusion Criteria
- Patients diagnosed with one of the following conditions: Schizophrenia, Bipolar disorders and Major depressive disorders.
Exclusion Criteria
- Patients who have not been diagnosed with the conditions as outlined in the Inclusion criteria.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie treatment response in schizophrenia and bipolar disorder cases analyzed in NCT01377896?
How do prescription patterns for antipsychotics and mood stabilizers in NCT01377896 compare to standard-of-care for major depressive disorders?
What biomarkers were associated with patient selection and treatment outcomes in AstraZeneca's observational study of psychiatric disorders?
What adverse events were reported in real-world management of schizophrenia and bipolar disorder in NCT01377896 cohort?
How do AstraZeneca's prescription strategies for psychiatric disorders compare with other pharmaceutical companies' approaches in similar observational studies?